ClinicalTrials.gg
CompletedNCT06649630VOYAGER1Updated Apr 1, 2026

A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men

A Phase 1 interventional study of NNC0442-0344 A and Placebo in Haemophilia A, sponsored by Novo Nordisk A/S. Completed at 2 sites in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 92 studies in Hemophilia A by Novo Nordisk A/S — 8 open to participants now, 12 under way, 5 of them phase 3. Hemophilia A · Novo Nordisk A/S.

Enrollment
13th of 59
95 · median 38
Started
2024
with 2 others
Phase 1
27 of 92
1 open now
Registered
86th of 92
by date

Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 13th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2024, is one of 27 in phase 1, and was the 86th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

8 of the 92 studies in Hemophilia A by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Hemophilia A by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study will test how different doses of study medicine (Inno8) work in the healthy men. The purpose of this study is to prove safety of Inno8 in healthy men, which will support further development of Inno8 in people with Haemophilia A. The study consists of three parts: single ascending dose (SAD), multiple ascending dose (MAD) and single subcutaneous dose (SSD). Each part will have more than one cohort (like sub-parts). No matter which part the participants will be enrolled in, they will either get the study medicine (Inno8) or a dummy medicine that looks like the study medicine but has no effect on the body (placebo). Which treatment participants get is decided by chance. The study medicine is a new medicine that cannot be prescribed by doctors. In the SAD and SSD part participants will receive a single injection of study medicine or placebo, and the study will last for up to 9 weeks. In the MAD part, participants will receive 1-2 tablets of study medicine or placebo daily for 10 days, and the study will last for up to 11 weeks.

03

Conditions studied

  • Haemophilia A

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male
  • Age 18-45 years (both inclusive) at the time of signing
  • between 18.5 and 29.9 Kilogram Per Square Meter (kg/m\^2) (both inclusive)
  • Body weight between 60.0 and 100.0 Kilogram (kg) (both inclusive)
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator

Exclusion criteria

Exclusion Criteria:

  • Factor VIII activity greater than or equal to (≥) 150% at screening
  • Increased risk of thrombosis, e.g. known history of personal or first-degree relative(s) with unprovoked deep vein thrombosis
  • Any clinical signs or established diagnosis of venous or arterial thromboembolic disease
  • Any of the thrombophilia markers listed below:
  • Protein C, protein S or antithrombin below the lower normal laboratory range
  • Factor II activity, activated protein C resistance, lupus anticoagulant, anti-cardiolipin antibody (IgG and IgM) or anti-β2 glycoprotein I antibody (IgG and IgM) outside the normal laboratory range at screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Cohort 1 (SAD): NNC0442-0344 A

    Participants will receive single dose of NNC0442-0344 A intravenously.

    Drug: NNC0442-0344 A

  • Experimental
    Cohort 2 (SAD): NNC0442-0344 A

    Participants will receive single dose of NNC0442-0344 A intravenously.

    Drug: NNC0442-0344 A

  • Experimental
    Cohort 3 (SAD): NNC0442-0344 A

    Participants will receive single dose of NNC0442-0344 A intravenously.

    Drug: NNC0442-0344 A

  • Experimental
    Cohort 4 (SAD): NNC0442-0344 A

    Participants will receive single dose of NNC0442-0344 A intravenously.

    Drug: NNC0442-0344 A

  • Experimental
    Cohort 5 (SAD): NNC0442-0344 A

    Participants will receive single dose of NNC0442-0344 A intravenously.

    Drug: NNC0442-0344 A

  • Experimental
    Cohort 1 (MAD): NNC0442-0344 A

    Participants will receive a oral daily dose of NNC0442-0344 A for 10 days.

    Drug: NNC0442-0344 A

  • Experimental
    Cohort 2 (MAD): NNC0442-0344 A

    Participants will receive a oral daily dose of NNC0442-0344 A for 10 days.

    Drug: NNC0442-0344 A

  • Experimental
    Cohort 3 (MAD): NNC0442-0344 A

    Participants will receive a oral daily dose of NNC0442-0344 A for 10 days.

    Drug: NNC0442-0344 A

  • Experimental
    Cohort 4 (MAD): NNC0442-0344 A

    Participants will receive a oral daily dose of NNC0442-0344 A for 10 days.

    Drug: NNC0442-0344 A

  • Experimental
    Cohort 1 (SSD): NNC0442-0344 A

    Participants will receive single dose of NNC0442-0344 A subcutaneously.

    Drug: NNC0442-0344 A

  • Experimental
    Cohort 2 (SSD): NNC0442-0344 A

    Participants will receive single dose of NNC0442-0344 A subcutaneously.

    Drug: NNC0442-0344 A

  • Placebo comparator
    SAD: Placebo

    Participants will receive single dose of placebo intravenously.

    Drug: Placebo

  • Placebo comparator
    MAD: Placebo

    Participants will receive a oral daily dose of Placebo for 10 days.

    Drug: Placebo

  • Placebo comparator
    SSD: Placebo

    Participants will receive single dose of placebo subcutaneously.

    Drug: Placebo

Interventions

  • SAD: NNC0442-0344 A will be administered intravenously. MAD: NNC0442-0344 A will be administered orally. SSD: NNC0442-0344 A will be administered subcutaneously.

    Also known as: Inno8

  • DrugPlacebo

    SAD: Placebo will be administered intravenously. MAD: Placebo will be administered orally. SSD: Placebo will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. SAD: Number of treatment emergent adverse events

    Measured as count of events.

    Time frame: From time of dosing (Day 1) to Day 36

  2. MAD: Number of treatment emergent adverse events

    Measured as count of events.

    Time frame: From time of dosing (Day 1) to end of follow-up (Day 46)

  3. SSD: Number of treatment emergent adverse events

    Measured as count of events.

    Time frame: From time of dosing (Day 1) to Day 36

Secondary outcomes

  1. SAD: Change in D-dimer

    Measured as absolute and percentage (%).

    Time frame: From baseline (Day 1) to Day 36

  2. SAD: Change in prothrombin fragment 1 and 2

    Measured as absolute and %.

    Time frame: From baseline (Day 1) to Day 36

  3. SAD: Change in fibrinogen

    Measured as absolute and %.

    Time frame: From baseline (Day 1) to Day 36

  4. SAD: Change in platelets

    Measured as absolute and %.

    Time frame: From baseline (Day 1) to Day 36

  5. SAD: Cmax, SD: the maximal concentration of Inno8 after a single dose

    Measured as nanograms per millilitre (ng/mL).

    Time frame: From baseline (Day 1) to Day 36

  6. SAD: AUC, SD: the area under the concentration curve of Inno8 after a single dose

    Measured as nanograms\*day per millilitre (ng\*day/mL).

    Time frame: From baseline (Day 1) to Day 36

  7. SAD: T1/2, SD: the terminal half-life of Inno8 after a single dose

    Measured as days.

    Time frame: From baseline (Day 1) to Day 36

  8. SAD: Maximum change in activated partial thromboplastin time

    Measured as seconds.

    Time frame: From baseline (Day 1) to Day 36

  9. SAD: Maximum thrombin generation (peak height)

    Measured as nanomolar (nM).

    Time frame: From baseline (Day 1) to Day 36

  10. MAD: Change in D-dimer

    Measured as absolute and %.

    Time frame: From baseline (Day 1) to Day 46

  11. MAD: Change in prothrombin fragment 1 and 2

    Measured as absolute and %.

    Time frame: From baseline (Day 1) to Day 46

  12. MAD: Change in fibrinogen

    Measured as absolute and %.

    Time frame: From baseline (Day 1) to Day 46

  13. MAD: Change in platelets

    Measured as absolute and %.

    Time frame: From baseline (Day 1) to Day 46

  14. MAD: Occurrence of anti-Inno8 antibodies

    Measured as count.

    Time frame: From baseline (Day 1) to Day 46

  15. MAD: Cmax: The maximum concentration of Inno8 after multiple doses

    Measured as ng/mL.

    Time frame: From Day 10 to Day 11

  16. MAD: Tmax: The time to Cmax after last multiple dose

    Measured as hours.

    Time frame: From Day 10 to Day 11

  17. MAD: Tmax: The time to Cmax after first dose

    Measured as hours.

    Time frame: From Day 1 to Day 2

  18. MAD: AUC: the area under the Inno8 concentration-time curve in the dosing interval after multiple doses

    Measured as ng\*day/mL.

    Time frame: From Day 10 to Day 11

  19. MAD: Maximum thrombin generation (peak height)

    Measured as nM.

    Time frame: From Day 10 to Day 11

  20. SSD: Change in D-dimer

    Measured as absolute and %.

    Time frame: From baseline (Day 1) to Day 36

  21. SSD: Change in prothrombin fragment 1 and 2

    Measured as absolute and %.

    Time frame: From baseline (Day 1) to Day 36

  22. SSD: Change in fibrinogen

    Measured as absolute and %.

    Time frame: From baseline (Day 1) to Day 36

  23. SSD: Change in platelets

    Measured as absolute and %.

    Time frame: From baseline (Day 1) to Day 36

  24. SSD: Cmax, SD: the maximal concentration of Inno8 after a single dose

    Measured as ng/mL.

    Time frame: From baseline (Day 1) to Day 36

  25. SSD: AUC, SD: the area under the concentration curve of Inno8 after a single dose

    Measured as ng\*day/mL.

    Time frame: From baseline (Day 1) to Day 36

  26. SSD: T1/2, SD: the terminal half-life of Inno8 after a single dose

    Measured as days.

    Time frame: From baseline (Day 1) to Day 36

  27. SSD: Maximum change in activated partial thromboplastin time

    Measured as seconds.

    Time frame: From baseline (Day 1) to Day 36

  28. SSD: Maximum thrombin generation (peak height)

    Measured as nanomolar (nM).

    Time frame: From baseline (Day 1) to Day 36

07

Study locations

2 sites
  • Charité - Campus Charité Mitte - Charité Research Organisation GmbH
    Berlin, 10117, Germany
  • Charité Research Organisation GmbH
    Berlin, 10117, Germany
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Mar 2026, 18 months.

Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 18 months is above that.

Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 21, 2024
StartActual
Sep 23, 2024
Primary completionActual
Mar 26, 2026
CompletionActual
Mar 26, 2026
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06649630
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 21, 2024
Start date
Sep 23, 2024
Primary completion
Mar 26, 2026
Completion
Mar 26, 2026
Last update
Apr 1, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0442-0344

Start the discussion